Implantica (IMP) Q4 2024 earnings summary

Executive summary

• Significant progress toward FDA approval for RefluxStop™, with favorable feedback on clinical modules and imminent final module submission; U.S. market entry preparations are underway.

• Over 1,000 surgeries performed and more than 40 hospitals in Europe using the device, with 15 new strategic accounts added in 2024, including major hospitals in Spain, Germany, Italy, and the UK.

• RefluxStop™ demonstrates outstanding long-term clinical results, with strong outcomes in controlled studies and real-world settings, including a published study showing significant reduction in PPI use and improved quality of life.

• Maintained robust liquidity and equity positions, with no interest-bearing debt and a strong cash position at year-end.

• Net sales for Q4 2024 decreased 13% to EUR 442k, but full-year sales rose 38% to EUR 1.94m year-over-year.

Financial highlights

• Q4 net sales: EUR 442k (down 13% year-over-year); full-year: EUR 1.94m (up 38%).

• Adjusted gross margin: 90% in Q4 (92% prior year); 92% for the year (94% prior year).

• Q4 operating loss (EBIT): EUR 7.17m (up 3%); full-year EBIT: EUR 25.47m (up 17%).

• Q4 net loss: EUR 7.34m (improved from EUR 8.73m); full-year net loss: EUR 23.69m (improved from EUR 24.50m).

• Cash and cash equivalents: EUR 64.6m at year-end; equity of EUR 100.2m; no interest-bearing debt.

Outlook and guidance

• Preparing for U.S. market entry pending FDA approval, with targeted engagement of top surgeons and hospitals and rapid pre-launch preparations.

• Ongoing cost-effectiveness analysis and payer policy reviews to support reimbursement and market access in the U.S.

• Business expected to continue growing, with substantial revenue opportunity dependent on U.S. approval or broad European reimbursement.

• Gross margin expected to remain high, with fluctuations due to subscale operations and free device programs.

• Potential for capital raise to accelerate U.S. launch is under consideration.